ArticleCancers2019
Ischemia Is Related to Tumour Genetics in Uveal Melanoma.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Bap1-mediated deubiquitination determines immune tolerance and anti-tumor immunity via modulating eTreg cell differentiation and ferroptosis.Cell death and differentiation · 2026Article
- Plant-Derived Exosome-Coated Niosome Oxygen Nanobubbles for the Mitigation of Ocular Ischemia.ACS pharmacology & translational science · 2025Article
- Investigating Vitreous Cytokines in Choroidal Melanoma.Cancers · 2023Article
- BAP1 is a novel regulator of HIF-1α.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Review
- HIF1Oxidative medicine and cellular longevity · 2022Article
- Association of TYRP1 with hypoxia and its correlation with patient outcome in uveal melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Expression of HDACs 1, 3 and 8 Is Upregulated in the Presence of Infiltrating Lymphocytes in Uveal Melanoma.Cancers · 2021Article
- Article
- Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.Trends in cancer · 2021Review
- Roles of the BAP1 Tumor Suppressor in Cell Metabolism.Cancer research · 2021Review
- Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.Investigative ophthalmology & visual science · 2021Article
- IFN-γ and CD38 in Hyperprogressive Cancer Development.Cancers · 2021Review
- Update on uveal melanoma: Translational research from biology to clinical practice (Review).International journal of oncology · 2020Review
- Uveal Melanoma.Cancers · 2019Article
- HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.Cancers · 2019Review
- Revealing a HeterozygousJournal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Hypoxia-inducible factor 1-alpha (HIF1a) and its regulator von Hippel-Lindau protein (VHL) play an important role in tumour ischemia. Currently, drugs that target HIF1a are being developed to treat malignancies. Although HIF1a is known to be expressed in uveal melanoma (UM), it is as yet unknown which factors, such as tumour size or genetics, determine its expression. Therefore, we aimed to determine which tumour characteristics relate to HIF1a expression in UM. Data from 64 patients who were enucleated for UM were analysed. Messenger RNA (mRNA) expression was determined with the Illumina HT-12 v4 chip. In 54 cases, the status of chromosomes 3 and 8q, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.